PZ Cormay

PZ Cormay Net Debt/FCF

The Net Debt to Free Cash Flow Ratio of PZ Cormay (CRM.WA) as of Oct 22, 2026 is -2.60. In the previous year, Net Debt to Free Cash Flow Ratio was -0.39 — a change of 562.09% (lower).

Net Debt/FCF

-2.60

YoY

562.09%

Last updated:

Net Debt to Free Cash Flow Ratio of PZ Cormay is 2025 -2.60 . Net Debt to Free Cash Flow Ratio of PZ Cormay was 2024 -0.39 . It decreases by 562.09% lower compared to the previous year.

The PZ Cormay Net Debt/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt/FCF
Date
Net Debt/FCF
Jan 1, 2018
-0.12 PLN
Jan 1, 2019
2.33 PLN
Jan 1, 2020
6.48 PLN
Jan 1, 2021
3.23 PLN
Jan 1, 2022
0.63 PLN
Jan 1, 2023
0.74 PLN
Jan 1, 2024
-0.39 PLN
Jan 1, 2025
-2.60 PLN
The PZ Cormay Net Debt/FCF history
YEARNet Debt/FCFYoY
-2.60+562.09%
-0.39-153.19%
0.74+16.54%
0.63-80.36%
3.23-50.14%
6.48+177.50%
2.33-2,009.13%
-0.12-9.72%
-0.14-151.03%
0.27-82.46%
1.51-106.46%
-23.44—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

PZ Cormay Stock analysis

What does PZ Cormay do? PZ Cormay SA manufactures diagnostic reagents and laboratory equipment, offering products like biochemical rapid tests, vacuette tubes, and devices including ACCENT-300, ACCENT-200, PRESTIGE 24i, LIVIA analyzers, MYTHIC 18 hematology analyzers, and IChem 100 urinalysis apparatus. The company serves clinical chemistry, hematology, electrophoresis, parasitology, cytology, coagulation, and specific protein recognition segments. Its products are distributed through Orphee SA, which acquired 100% stake in TT Management Sp z o o on September 1, 2014, to transfer Cormay group's production and distribution activities. Orphee SA, now holding full control of Cormay's operations, manages the distribution of PZ Cormay SA's diagnostic reagents and laboratory equipment. The firm's revenue comes from selling biochemical analyzers, hematology analyzers, and related products to healthcare facilities and laboratories. PZ Cormay SA's product portfolio includes drugs, biochemical rapid tests, and devices such as vacuette tubes, targeting clinical and diagnostic markets with a focus on specialized equipment for medical analysis. The company's revenue streams are derived from the sale of its analytical devices and reagents, with Orphee SA handling the distribution after the 2014 restructuring. PZ Cormay SA's products are used in clinical chemistry, hematology, and other diagnostic segments, with specific equipment like the ACCENT-300 and MYTHIC 18 being key offerings. The restructuring plan transferred production and distribution to Orphee SA, enabling streamlined operations and market access. PZ Cormay is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PZ Cormay stock

Net Debt to Free Cash Flow Ratio of PZ Cormay is -2.60 in 2025.

Net Debt to Free Cash Flow Ratio of PZ Cormay changed from -0.39 to -2.60, representing a 562.09% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to Free Cash Flow Ratio PZ Cormay since 2006 – with annual values, charts, and detailed analysis.

Net Debt/FCF indicates how many years it would take to repay net debt using free cash flow. Lower ratios suggest faster deleveraging potential.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to Free Cash Flow Ratio's PZ Cormay with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — PZ Cormay

All Key Metrics — PZ Cormay